Gemini Therapeutics Signs a Research Agreement with SERI to Identify New Therapies for Age-related Macular Degeneration
Shots:
- SERI and Gemini will investigate the link b/w genetic & potential biomarkers in patients with PCV. The collaboration leverages Gemini’s experience of precision medicine to develop therapies targeting the genetically defined patients
- The agreement explores the molecular impact of specific genes linked to PCV which provide information in designing new therapies in future
- Gemini is currently working on GEM103- a recombinant Complement Factor H therapy for dry AMD which the initiation point to develop therapies targeting the unmet medical needs of patients
Click here to read full press release/ article | Ref: Business wire | Image: Acrofan
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com